4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of "Moderate Buy" by Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $26.71.

Several research firms recently issued reports on FDMT. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday, April 8th. Royal Bank of Canada dropped their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research report on Monday, March 3rd. Bank of America decreased their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. BMO Capital Markets cut 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, Chardan Capital lowered their price target on 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 4D Molecular Therapeutics in the fourth quarter worth about $50,000. PNC Financial Services Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after purchasing an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock valued at $55,000 after purchasing an additional 9,737 shares during the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at approximately $56,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Stock Performance

FDMT traded down $0.16 during midday trading on Friday, hitting $2.94. The stock had a trading volume of 67,691 shares, compared to its average volume of 827,226. The company has a market cap of $136.13 million, a P/E ratio of -1.04 and a beta of 2.89. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93. The business has a fifty day moving average of $3.90 and a 200 day moving average of $6.02.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). On average, equities research analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.